EUVIMEDEUVIMED entdecken
Vergleichsstudie

Preclinical study and first-in-human imaging of [18F]FAP-2286, and comparison with 2-[18F]FDG PET/CT in various cancer patients

Lifang Liu, Jiawei Zhong, Ziqi Zhang, Xiaoting Ye, Xinlu Wang, Shaoyu Liu, Zhanwen Zhang

European Journal of Nuclear Medicine and Molecular Imaging · 2024-06 · 51 (7) · 2012-2022

DOI: 10.1007/s00259-024-06626-9 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 08.02.2024. Verfasst von Lifang Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine Department, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510120, China. Hauptthemen laut MEDLINE: Fluorodeoxyglucose F18, Positron Emission Tomography Computed Tomography, Neoplasms. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province, Basic and Applied Basic Research Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Fibroblast-activated protein (FAP) is highly expressed in cancer-associated fibroblasts (CAFs) of many solid cancers, but low or absent in normal tissues. Our study aimed to develop a novel FAP-specific tracer, namely [18F]FAP-2286, and evaluated its performance in comparison with well-established agents such as [18F]FAPI-42 and [68Ga]Ga-FAP-2286 in preclinical research, as well as 2-[18F]FDG in pilot clinical study. METHODS: [18F]FAP-2286 was manually synthesized in accordance with Good Manufacturing Practice (GMP). Subsequent investigations encompassed cell uptake, competitive binding affinity, internalization and efflux assays using HT-1080hFAP cell lines. PET imaging and biodistribution studies were conducted in HEK-293ThFAP, A549hFAP, HT-1080hFAP tumor-bearing mice as well as HEK-293T, A549 and HT-1080 control groups. Furthermore, clinical evaluation of [18F]FAP-2286 was performed in fifteen patients with various cancers compared to 2-[18F]FDG PET. RESULTS: The radiolabeling yield of [18F]FAP-2286 was 30.53 ± 5.20%, with a radiochemical purity exceeding 97%. In cell assays, [18F]FAP-2286 showed specific uptake, high internalization fraction and low cellular efflux. Rapid tumor uptake and satisfactory tumor retention was observed on micro-PET imaging and cancer patients. Meanwhile, the clinical research demonstrated that [18F]FAP-2286 may represent an alternative for low glucose-metabolism malignant tumors PET imaging such as gastric cancers. CONCLUSION: [18F]FAP-2286 showed superior imaging quality including rapid and high target uptake and satisfactory retention in both tumor-bearing mice and cancer patients. It may emerge as a promising candidate for early or delayed phase imaging and 2-[18F]FDG non-avid cancers PET scan.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fluorodeoxyglucose F18Positron Emission Tomography Computed TomographyNeoplasmsHumansAnimalsMiceMaleFemaleCell Line, TumorHEK293 CellsTissue DistributionMiddle AgedRadiopharmaceuticalsAgedMembrane ProteinsEndopeptidasesFibroblast Activation Protein Alpha

Stichwörter der Autor:innen

Al18F-PET/CTClinical conversionFAP-2286Fibroblast activation protein-α

Substanzen

Fluorodeoxyglucose F18RadiopharmaceuticalsMembrane ProteinsEndopeptidasesFibroblast Activation Protein Alpha

Autor:innen und Institutionen

  • Nuclear Medicine Department, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510120, China.
  • Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510120, China.
  • Department of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China.
  • Department of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China. 71lu@163.com.
  • Department of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China. shaoyuliu@tju.edu.cn.
  • Nuclear Medicine Department, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510120, China. zhzhanw7@mail.sysu.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Guangdong Province
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Science and Technology Project of Guangzhou City
  • State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia&The First People's Hospital of Kashi Fund
  • Zhong Nanshan Medical Foundation of Guangdong Province
  • State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia&The First People’s Hospital of Kashi Fund

Zitieren

APA

Liu, L., Zhong, J., Zhang, Z., Ye, X., Wang, X., Liu, S., & Zhang, Z. (2024). Preclinical study and first-in-human imaging of [18F]FAP-2286, and comparison with 2-[18F]FDG PET/CT in various cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 51(7), 2012-2022. https://doi.org/10.1007/s00259-024-06626-9

Vancouver

Liu L, Zhong J, Zhang Z, Ye X, Wang X, Liu S, et al. Preclinical study and first-in-human imaging of [18F]FAP-2286, and comparison with 2-[18F]FDG PET/CT in various cancer patients. European Journal of Nuclear Medicine and Molecular Imaging. 2024;51(7):2012-2022. doi:10.1007/s00259-024-06626-9

BibTeX
@article{Liu2024,
  author = {Liu, Lifang and Zhong, Jiawei and Zhang, Ziqi and Ye, Xiaoting and Wang, Xinlu and Liu, Shaoyu and Zhang, Zhanwen},
  title = {Preclinical study and first-in-human imaging of [18F]FAP-2286, and comparison with 2-[18F]FDG PET/CT in various cancer patients},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2024},
  volume = {51},
  number = {7},
  pages = {2012--2022},
  doi = {10.1007/s00259-024-06626-9}
}
Kostenlos starten →